Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jun 07, 2014 11:03am
164 Views
Post# 22639913

RE:Don

RE:DonHi Storm23.

I agree. As I've observed businesses over the years it is very often the case that the founders who got an organization started get to a stage where they are not capable of taking it to the next level. I sense, based on the lack of communicatiion and lack of progress in the past year that Don is not capable of taking RVX to the next level.

That being said, both Eastern and NGN, who could have been turning up the heat on Don, seem to have confidence in him IMO at this stage.

Great science + huge market - ineffective leadership - lack of communication = low share price.

I would love to wear egg on my face and get the surprise of my life when Don announces a huge and brilliant CVR, trial funding, etc in the next week.

Cheers
Toinv
Bullboard Posts